Navigation Links
Cambrex To Announce Second Quarter 2009 Financial Results on August 4, 2009

EAST RUTHERFORD, N.J., July 28 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced that second quarter 2009 financial results will be released on Tuesday, August 4, 2009 after the market closes.

The Company will host a conference call to discuss the second quarter 2009 financial results.

                  Second Quarter 2009 Earnings Conference Call

    When:            Wednesday, August 5, 2009 at 8:30 a.m. Eastern Time

    Dial-in:         1-888-634-4003 for U.S.
                     1-706-634-6653 for International
                     Pass code:  21874877

    Dial-in Replay:  1-800-642-1687 for U.S.
                     1-706-645-9291 for International
                     Pass code:  21874877
                     Available through Wednesday, August 12, 2009

                     Available for 30 days following the conference call

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including active pharmaceutical ingredients ("API"), advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. For more information, please visit

SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cambrex Regains Compliance With Revised NYSE Listing Standards
2. Cambrex Reports Fourth Quarter and Full Year 2008 Results
3. Cambrex to Announce Fourth Quarter 2008 Financial Results on February 11, 2009
4. Skinvisible and Cambrex Enter Into Agreement to Develop Acne Products
5. Cambrex Presentation at The JPMorgan Healthcare Conference to be Webcast
6. Cambrex to Announce First Quarter 2008 Financial Results on May 1, 2008
7. Cambrex Customer Announced Recall
8. Cambrex Reports Fourth Quarter and Full-Year 2007 Results
9. Cambrex Signs Agreement To Acquire ProSyntest AS
10. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
11. Inverness Medical Innovations Announces Second Quarter 2009 Results
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: